Interferon-β1b in multiple sclerosis

Expert Review of Neurotherapeutics

Volumn 7, Issue 3, 2007, Pages 227-239

  Buttmann, Mathias ^a   Rieckmann, Peter ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

Adverse effect; Clinical trial; Interferon ; Mechanism of action; Multiple sclerosis; Pharmacodynamics; Pharmacokinetics

Indexed keywords

AZATHIOPRINE; BETA INTERFERON; BETA1A INTERFERON; BIOLOGICAL MARKER; CLADRIBINE; FINGOLIMOD; GLATIRAMER; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; INTERFERON BETA SERINE; MITOXANTRONE; MONOCLONAL ANTIBODY; NATALIZUMAB; PLACEBO; RALENOVA; UNCLASSIFIED DRUG; IMMUNOLOGICAL ADJUVANT; INTERFERON BETA-1B;

CEREBROSPINAL FLUID ANALYSIS; CHILL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG ACTIVITY; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG FORMULATION; DRUG MECHANISM; DRUG RESEARCH; DRUG SYNTHESIS; DRUG WITHDRAWAL; ERYTHEMA; FATIGUE; FEVER; FLU LIKE SYNDROME; FOLLOW UP; HEADACHE; HUMAN; IMMUNOMODULATION; INFLAMMATORY DISEASE; INJECTION SITE REACTION; INSOMNIA; LIVER FUNCTION TEST; MULTIPLE SCLEROSIS; MYALGIA; NAUSEA; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; RANDOMIZED CONTROLLED TRIAL; REVIEW; SIDE EFFECT; SKIN NECROSIS; STRUCTURE ACTIVITY RELATION; SWEATING; TREATMENT RESPONSE; WEAKNESS; WELLBEING; CLINICAL PRACTICE; IMMUNOLOGY; PRACTICE GUIDELINE; TREATMENT OUTCOME;

ADJUVANTS, IMMUNOLOGIC; CLINICAL TRIALS; HUMANS; INTERFERON-BETA; MULTIPLE SCLEROSIS; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES; TREATMENT OUTCOME;

EID: 33947191425     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/14737175.7.3.227     Document Type: Review

References (19)

1. Compston A, Coles A. Multiple sclerosis. Lancet 359(9313), 1221-1231 (2002).
2. Pugliatti M, Rosati G, Carton H et al. The epidemiology of multiple sclerosis in Europe. Eur. J. Neurol. 13(7), 700-722 (2006).
3. Sadovnick AD, Ebers GC. Epidemiology of multiple sclerosis: a critical overview. Can. J. Neurol. Sci. 20(1), 17-29 (1993).
4. Bronnum-Hansen H, Stenager E, Hansen T, Koch-Henriksen H. Survival and mortality rates among Danes with MS. Int. MS J. 13(2), 66-71 (2006).
5. Frohman EM, Racke MK, Raine CS. Multiple sclerosis - the plaque and its pathogenesis. N. Engl. J. Med. 354(9), 942-955 (2006). • Current review on the pathogenesis of multiple sclerosis (MS).
6. Minden SL, Frankel D, Hadden L, Perloffp J, Srinath KP, Hoaglin DC. The Sonya Slifka longitudinal multiple sclerosis study: methods and sample characteristics. Mult. Scler. 12(1), 24-38 (2006).
7. Ramsaransing GS, De Keyser J. Benign course in multiple sclerosis: a review. Acta Neurol. Scand. 113(6), 359-369 (2006).
8. Rovaris M, Confavreux C, Furlan R, Kappos L, Comi G, Filippi M. Secondary progressive multiple sclerosis: current knowledge and future challenges. Lancet Neurol. 5(4), 343-354 (2006).
9. Montalban X. Primary progressive multiple sclerosis. Curr. Opin. Neurol. 18(3), 261-266 (2005).
10. Thompson AJ, Montalban X, Barkhof F et al. Diagnostic criteria for primary progressive multiple sclerosis: a position paper. Ann. Neurol. 47(6), 831-835 (2000).
11. Gayou A, Brochet B, Dousset V. Transitional progressive multiple sclerosis: a clinical and imaging study. J. Neurol. Neurosurg. Psychiatr. 63(3), 396-398 (1997).
12. Ingle GT, Stevenson VL, Miller DH et al. Two-year follow-up study of primary and transitional progressive multiple sclerosis. Mult. Scler. 8(2), 108-114 (2002).
13. McDonald WI, Compston A, Edan G et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the international panel on the diagnosis of multiple sclerosis. Ann. Neurol. 50(1), 121-127 (2001).
14. Polman CH, Reingold SC, Edan G et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". Ann. Neurol. 58(6), 840-846 (2005). • 2005 update of McDonald diagnostic criteria from 2001.
15. Dalton CM, Brex PA, Miszkiel KA et al. Application of the new McDonald criteria to patients with clinically isolated syndromes suggestive of multiple sclerosis. Ann. Neurol. 52(1), 47-53 (2002).
16. Poser CM, Paty DW, Scheinberg L et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann. Neurol. 13(3), 227-231 (1983).
17. Rieckmann P, Toyka KV, Bassetti C et al. Escalating immunotherapy of multiple sclerosis - new aspects and practical application. J. Neurol. 251(11), 1329-1339 (2004).
18. Rieckmann P. Escalating immunomodulatory therapy of multiple sclerosis: update (September 2006). Nervenarzt 77(12), 1506-1518 (2006).
19. Group IMSS. Interferon β-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group. Neurology 43(4), 655-661 (1993).